Asda Selects Blue Yonder’s Order Management to Accelerate its Omni-Channel Transformation
24.5.2022 13:00:00 EEST | Business Wire | Press release
Having selected Blue Yonder last year to digitally transform its end-to-end supply chain and retail operations, Asda, one of Britain’s leading retailers with a unique position in the market, is continuing its retail transformation journey with Blue Yonder by selecting Luminate® Commerce solutions to modernize its order management capabilities. Asda will also partner with Bringg, a Blue Yonder technology alliance partner and the leading delivery and fulfillment cloud platform, to make each element of the supply chain seamless, connected and orchestrated.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005263/en/
Asda consists of supercenters, superstores, and smaller supermarkets. The retailer also runs petrol filling stations and Asda Living stores, which offer its popular George clothing and home merchandise lines. The company employs more than 140,000 colleagues serving more than 16 million customers who shop in its stores and online weekly.
With Blue Yonder’s order management (OMS) microservices, Asda will be able to:
- Process orders faster to improve the customer experience.
- Provide customers with real-time inventory visibility from the beginning of the shopping experience, as well as pre-sourcing fulfillment options.
- Connect with the entire supply chain, considering the capacity to fulfill demand across any channel, at any time.
- Provide dynamic slotting options to the end customer for both home deliveries and pickup in store.
“Omni-channel is at the heart of our strategy and customer proposition, where we want to provide a great customer experience and a seamless user journey. We have been extremely impressed by Blue Yonder’s OMS microservices, which we will deploy across our grocery, clothing and general merchandise segments,” said Carl Dawson, chief information officer, Asda.
Blue Yonder’s flexible OMS microservices, powered by machine learning and artificial intelligence, will help Asda optimize the entire click-to-deliver journey, starting with an engaging customer experience through efficient order fulfillment. With Bringg, Asda will be able to optimize its last-mile operations to deliver on-time to meet customer expectations. The combination will support Asda’s home delivery service, click and collect proposition, as well as new channels such as express commerce platforms.
“Asda is leading a game-changing retail transformation focused on customer centricity, from first to last mile. We are very excited to extend our relationship with Asda into an area where we are connecting e-commerce with a true omni-channel landscape. Our modern OMS microservices are engineered to scale, perform and operate under the highest volumes seen on the market. Our OMS microservices, SaaS native, API-first components leverage the latest technology and engineering to speed up our clients’ transformations. We believe that this will help Asda to continue to modernize its business and invest in customer proposition,” said Gael Ramaen, vice president, commerce, Blue Yonder.
“The challenges and complexities of faster, more convenient and on-demand order orchestration, delivery and fulfillment are grand,” said Nikolai Avrutov, vice president Alliances, Bringg. “In order to achieve game-changing capabilities on these fronts, retailers need their technology vendors to work closely together and to relentlessly raise the bar for its mutual customers through tight collaboration and strategic co-innovation. We are proud to be doing just that with Blue Yonder for Asda.”
Additional Resources:
- Learn more about Luminate Commerce and the order management (OMS) microservices
- Learn how migrating to the cloud can digitally transform your supply chain
- Learn how Bringg’s Delivery Hub transforms your delivery orchestration with ease
About Asda Stores Ltd.
Founded in the 1960s in Yorkshire, Asda is the UK’s third largest supermarket and was acquired by the Issa Brothers and TDR Capital Ltd in 2021.
Each week more than 16 million customers visit its 640 stores - including Supercentres, Superstores, Supermarkets, Asda Living stores, and standalone petrol stations - and are served by over 140,000 colleagues. www.asda.com and www.george.com deliver to 99% of the UK’s homes and to its 538 click and collect sites across the UK.
Its main office is in Leeds, Yorkshire and its George clothing division is in Lutterworth, Leicestershire.
About Bringg
Bringg helps enterprises scale up and optimize their logistics operations with our data-led delivery and fulfillment cloud platform. Using Bringg, retailers and logistics providers can rapidly enable innovative delivery and fulfillment models that maximize the customer experience, optimize logistics operations and scale business channels for growth. Some of the world’s best-known brands in more than 50 countries use Bringg’s platform to deliver the perfect last mile experience at peak efficiency across multiple delivery models. https://www.bringg.com
About Blue Yonder
Blue Yonder is the world leader in digital supply chain and omni-channel commerce fulfillment. Our intelligent, end-to-end platform enables retailers, manufacturers and logistics providers to seamlessly predict, pivot and fulfill customer demand. With Blue Yonder, you can make more automated, profitable business decisions that deliver greater growth and re-imagined customer experiences. Blue Yonder - Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005263/en/
Contact information
Blue Yonder: Marina Renneke, APR, +1 480-308-3037, marina.renneke@blueyonder.com
Bringg: Ashleigh Farber, +972542332099, ashleigh@bringg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom